MAPT and Alzheimer disease: In the Alzheimer Association International Conference, in July 2023, the diagnosis of biological AD was proposed to be used in clinical practice.33According to this proposal, the presence of AD pathophysiology identified by biomarkers in CSF, neuroimaging (amyloid PET and/or tau PET), and/or plasma biomarkers, would allow the diagnosis of “biological AD,” when there are suggestive clinical signs or even in their absence.